Novo Nordisk (NVO) executive Camilla Sylvest is departing the drugmaker after 28 years, Bloomberg’s Sara Sjolin reports. Sylvest has served as executive vice president for commercial strategy and corporate affairs for the last seven years, and was close to CEO Lars Fruergaard, Sjolin writes. Her exit comes after Morten Lammert resigned in March to take up a new role at rival Roche (RHHBY). Following Sylvest’s exit, Ludovic Helfgott will take over responsibility for commercial strategy and Thilde Hummel Bogebjerg has been promoted to executive vice president for quality, IT and environmental affairs, the report adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Eli Lilly threatens Zepbound copycat makers after shortage, Bloomberg reports
- Biotech Alert: Searches spiking for these stocks today
- Novo Nordisk Stock (NVO) Drops Despite Positive GLP-1 Trial Data
- Novo Nordisk’s Market Leadership Bolstered by Strong Product Data and Promising Future Assets
- Novo Nordisk Reports Strong 2024 Growth and Strategic Resolutions at AGM